Mechanisms of KRAS Inhibitor Resistance in KRAS-Mutant Colorectal Cancer Harboring Her2 Amplification and Aberrant KRAS Localization

Scientists investigated intrinsic resistance mechanisms to KRAS inhibitors using patient-derived colorectal cancer cells (CRC-PDCs). They found that KRAS-mutated CRC-PDCs could be divided into at least an EGFR pathway-activated group and a PI3K/AKT pathway-activated group.